Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Beyond immune checkpoint blockade: emerging immunological strategies

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Next-generation combination approaches for immune checkpoint therapy

The future of immune checkpoint therapy

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy

Emerging immune checkpoint and its combination therapy in cancer treatment

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Immune Checkpoints in Cancers: From Signaling to the Clinic

Immunotherapy - Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Small Molecule- and Peptide-Based Approaches

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness